Stef Heylen
Directeur/Bestuurslid bij Exevir Bio BV
Oorsprong van het eerstegraads netwerk van Stef Heylen
Entiteit | Type entiteit | Industrie | |
---|---|---|---|
Exevir Bio BV
Exevir Bio BV Pharmaceuticals: MajorHealth Technology Exevir Bio BV is engaged in biotechnology services. The company is headquartered in Zwijnaarde, Belgium.
9
| Holding Company | Pharmaceuticals: Major | 9 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Stef Heylen via zijn persoonlijke netwerk
Onderneming | Sector | Gelieerde personen | Hoofdpost |
---|---|---|---|
Corixa Corp.
Corixa Corp. BiotechnologyHealth Technology Corixa Corp. operates as a biopharmaceutical company. It develops and manufactures oncology and immunology products. The firm offers vaccines, immunotherapeutic, monoclonal antibody-based therapeutics, adjuvant and antigen delivery systems, toxin-conjugated, and antigen-specific diagnostic products. The company was founded by Steven H. Gillis and Mark McDade in 1994 and is headquartered in Hamilton, MT. | Biotechnology | Chairman | |
AIDS Healthcare Foundation
AIDS Healthcare Foundation Investment Trusts/Mutual FundsMiscellaneous AIDS Healthcare Foundation is a non-profit organization which engages in the provision of medicine and advocacy programs for HIV/AIDS. The firm offers HIV and STD testing, thrift store, dental clinic, and healthcare center services. The company was founded by Michael Weinstein in 1987 and is headquartered in Los Angeles, CA. | Investment Trusts/Mutual Funds | Director/Board Member | |
Aeras Global TB Vaccine Foundation
Aeras Global TB Vaccine Foundation Miscellaneous Commercial ServicesCommercial Services Aeras Global TB Vaccine Foundation is a non-profit organization, which engages in the development of tuberculosis vaccines in partnership with other biotech, pharmaceutical, and academic organizations. Its product pipeline includes AdS Ag85A, MTBCAV, VPM 1002, and RUTI. The company is headquartered in Rockville, MD. | Miscellaneous Commercial Services | Director/Board Member | |
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Neurona Therapeutics, Inc.
Neurona Therapeutics, Inc. BiotechnologyHealth Technology Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA. | Biotechnology | Director/Board Member | |
Johnson & Johnson Innovation - JJDC, Inc.
Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Investment Managers | Private Equity Investor | |
UCB | Pharmaceuticals: Major | Chairman | |
University College Dublin | College/University | Undergraduate Degree | |
ABLYNX | Biotechnology | Chief Tech/Sci/R&D Officer | |
FINANCIÈRE DE TUBIZE S.A. | Financial Conglomerates | Director/Board Member | |
Ogeda SA
Ogeda SA Pharmaceuticals: MajorHealth Technology Ogeda SA discovers and develops small molecule drugs. It develops NK3 antagonists for the treatment of hormone-dependent pathologies in the field of Women's Health. The company was founded in 1994 and is headquartered in Gosselies, Spain. | Pharmaceuticals: Major | Director/Board Member | |
LIFE HEALTHCARE GROUP HOLDINGS LIMITED | Hospital/Nursing Management | Director/Board Member | |
The Global Fund to Fight AIDS, Tuberculosis & Malaria | Miscellaneous Commercial Services | Director/Board Member | |
Altamar Private Equity SGIIC SA /Private Equity/
Altamar Private Equity SGIIC SA /Private Equity/ Investment ManagersFinance Altamar Private Equity SGIIC SA (Altamar Private Equity) is a private equity arm of Altamar Capital Partners SL founded in 2004. The firm is headquartered in Spain with additional offices in New York and Santiago de Chile. | Investment Managers | Private Equity Investor | |
MERUS N.V. | Biotechnology | Director/Board Member | |
Waaroost NV | Director/Board Member | ||
CANTARGIA AB | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
University of Antwerp | College/University | Doctorate Degree | |
Seroba BioVentures Ltd.
Seroba BioVentures Ltd. Investment ManagersFinance Seroba BioVentures Ltd (Seroba BioVentures) is a venture capital subsidiary of Kernel Management Partners Ltd founded in 2001 by Peter Sandys and Seamus O''Hara. The firm is headquartered in Dublin, Ireland. | Investment Managers | Private Equity Investor | |
TopiVert Ltd.
TopiVert Ltd. BiotechnologyHealth Technology TopiVert Ltd. develops topical treatments for inflammatory diseases of the eye and gut. Its application is used in the treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and other inflammatory diseases of the lungs. The company was founded by Eric Charles Meldrum in 2011 and is headquartered in London, the United Kingdom. | Biotechnology | Director/Board Member | |
The Francis Crick Institute Ltd.
The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Medical/Nursing Services | Director/Board Member | |
Asceneuron SA
Asceneuron SA Pharmaceuticals: MajorHealth Technology Asceneuron SA operates as a biotechnology company. It develops therapeutics for orphan tauopathis and Alzheimer?s disease. The firm specializes in small molecule drug discovery for neurodegenerative diseases. The company was founded by Dirk Beher, Frank Murdoch Armstrong and Christoph Wiessner in October 2012 and is headquartered in Lausanne, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Harvard Business School | College/University | Masters Business Admin | |
Pulmocide Ltd.
Pulmocide Ltd. Pharmaceuticals: MajorHealth Technology Pulmocide Ltd. provides biopharmaceutical services. It develops inhaled medicines for viral and fungal infections of the respiratory tract. The company was founded by William Garth Rapeport, John Murray, Kazuhiro Ito, and Peter Strong on March 23, 2007 and is headquartered in London, the United Kingdom. | Pharmaceuticals: Major | Director/Board Member | |
Solvay Business School of Economics & Management | College/University | Graduate Degree | |
Novadip Biosciences SA
Novadip Biosciences SA BiotechnologyHealth Technology Novadip Biosciences SA operates as a advanced biopharmaceutical company that develops cell-based therapies to treat patients with critical size bone defects and severe bone diseases. Its proprietary product, Creost, is a natural scaffold-free and tridimensional bone structure, which reconstructs large bone defects without the need of any biomaterial. The firm is a osteogenic living implant with a mineralization similar to a real bone. Its Creost is an autologous cell based-therapy product obtained from Adipose-derived Mesenchymal Stem Cells (AMSCs) which promotes (i) a perfect engraftment without any scaffold and (ii) a tissue remodeling with all native bone properties. Novadip Biosciences was founded by Jean-Fran?ois Pollet and Denis Dufrane in 2013 and is headquartered in Louvain-la-Neuve, Belgium. | Biotechnology | Director/Board Member | |
Minoryx Therapeutics SL
Minoryx Therapeutics SL BiotechnologyHealth Technology Minoryx Therapeutics SL engages in the development of drugs for the orphan genetic diseases of the central nervous system. The company was founded by Marc Martinell, Joan Aymami, Nigel Ten Fleming and Xavier Barril in 2011 and is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member | |
BIOCARTIS GROUP NV | Medical Specialties | Director/Board Member | |
Fund+
Fund+ Investment ManagersFinance Fund+ is an independent Venture Capital firm founded in 2015. The firm is headquartered in Leuven, Belgium. | Investment Managers | Private Equity Investor | |
Aelix Therapeutics SL
Aelix Therapeutics SL BiotechnologyHealth Technology Aelix Therapeutics SL researches and develops therapies for HIV. It develops therapeutic vaccines and immunotherapies to treat HIV infection. The firm is a spin-off of HIVACAT, the Catalan project for the development of effective vaccines against HIV. The company was founded by Christian Brander, Bonaventura Clotet, Josep Maria Gatell and Jordi Naval is headquartered in Barcelona, Spain. | Biotechnology | Director/Board Member Director/Board Member | |
eTheRNA immunotherapies NV
eTheRNA immunotherapies NV BiotechnologyHealth Technology eTheRNA immunotherapies NV develops novel immunotherapies to overcome cancers and infectious diseases. The company was founded by Carlo Heirman, Kris Thielemans and Sonja van Meirvenne in January 21, 2013 and is headquartered in Niel, Belgium. | Biotechnology | Director/Board Member | |
Horama SA
Horama SA BiotechnologyHealth Technology Horama SA engages in the development of gene therapies, It focuses on ophthalmological diseases for preserving visual autonomy of patients. The company was founded by Denis Cayet, Christian Hamel, Guylene Le Meur, Philippe Moullier, Vasiliki Kalatzis, and Michel Weberin March 2014 and is headquartered in Paris, France. | Biotechnology | Director/Board Member | |
StrideBio, Inc.
StrideBio, Inc. BiotechnologyHealth Technology Stridebio, Inc. focuses on creating and developing novel adeno-associated viral vector technologies. The company was founded by Aravind Asokan, Mavis Agbandje-McKenna and Patrick Ritschel and is headquartered in Durham, NC. | Biotechnology | Director/Board Member | |
Highlight Therapeutics SL
Highlight Therapeutics SL Pharmaceuticals: MajorHealth Technology Highlight Therapeutics develops ribonucleic acid-based therapies and novel targets in cancer and immune cells. Its product BO-112, induces immunogenic cell death in solid tumors and simultaneously activates the innate immune system to ensure optimal antigen processing and presentation to the adaptive immune system. The company was founded by Damia tormo Carulla and is headquartered in Paterna, Spain. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer | |
S-Biomedic NV
S-Biomedic NV Household/Personal CareConsumer Non-Durables Part of maxingvest AG, S-Biomedic NV is a Belgian company that develops skin microbiome manipulation technology which allows to transplant beneficial bacteria on the skin. The company is based in Beerse, Belgium. The company was founded in 2014 by Bernhard Päetzold, Veronika Oudova, Marc Guëll. Veronika Oudova has been the CEO since 2014. S-Biomedic was acquired by Beiersdorf AG on December 16, 2022. | Household/Personal Care | Director/Board Member | |
SpliceBio SL
SpliceBio SL BiotechnologyHealth Technology SpliceBio SL is a genetic medicines company based in Barcelona, Spain. The Spanish company harnesses its proprietary protein splicing platform to develop the next generation of gene therapies. SpliceBio's platform offers the potential to address diseases that currently cannot be treated with gene therapies because the necessary gene is too large to be delivered by -associated virus (AAV) vectors. The company's lead program targets Stargardt disease, a genetic eye disease that causes vision loss in children and adults. SpliceBio's platform is based on technology developed in the Muir lab at Princeton University after more than 20 years of pioneering intein and protein engineering research. The company was founded by Dominguez Silvia Frutos, Miquel Vila-Perelló, and Miquel Vila-Perelló has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
UCB Ventures (Private Equity)
UCB Ventures (Private Equity) Investment ManagersFinance UCB Ventures is the venture capital arm of UCB SA and was founded in 2016. UCB Ventures is headquartered in Brussels, Belgium with additional offices in Boston, Massachusetts and London, United Kingdom. | Investment Managers | Director/Board Member | |
UCB Ventures London | Investment Managers | Private Equity Investor Private Equity Investor | |
Calypso Biotech BV
Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Biotechnology | Director/Board Member | |
Sapreme Technologies BV
Sapreme Technologies BV BiotechnologyHealth Technology Sapreme Technologies BV operates as a biotech company that develops a platform technology to enable cytosolic delivery of macromolecule therapeutics. The company was founded by Ruben Postel in 2016 and is headquartered in Utrecht, the Netherlands. | Biotechnology | Chairman | |
Rinri Therapeutics Ltd.
Rinri Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Rinri Therapeutics Ltd. operates as a biotechnology company developing a novel cell-based therapy to restore hearing. The company was founded in 2018 and is headquartered in Sheffield, the United Kingdom. | Miscellaneous Commercial Services | Director/Board Member | |
Augustine Therapeutics NV
Augustine Therapeutics NV Medical/Nursing ServicesHealth Services Augustine Therapeutics NV is a Belgian company that focuses on developing innovative therapies for neuromuscular and neurodegenerative diseases. The company is based in Leuven, Belgium. The company's main focus is on HDAC6, a class II histone deacetylase, which is a well-known molecular target in various diseases, particularly neurodegenerative disorders and neuropathies. The company was founded in 2019, and Sylvain Celanire has been the CEO of the company since 2020. | Medical/Nursing Services | Director/Board Member | |
TRex Bio Ltd.
TRex Bio Ltd. BiotechnologyHealth Technology TRex Bio Ltd. is a British company that provides biotechnology research and development services. The private company is based in London, UK. The company was founded in 2018 by Houman Ashrafian. | Biotechnology | Director/Board Member | |
AviadoBio Ltd.
AviadoBio Ltd. BiotechnologyHealth Technology AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021. | Biotechnology | Chairman | |
Dendrogenix SA
Dendrogenix SA Pharmaceuticals: MajorHealth Technology Dendrogenix SA is a Belgian Belgium-based biotech company founded in 2018 that designs, develops, and brings proprietary molecules called dendrogenins to patients in the fields of hearing loss and neurology. The company is based in Liege, Belgium. Dendrogenins are cholesterol derivatives that stimulate cell differentiation in the immune and nervous system and induce growth of dendrites on dendritic cell and neuron precursors. The company has developed strong know-how in the chemical and biological aspects of dendrogenins. The company was founded by Stéphane Silvente, Gérard Tobelem, and Philippe Lefèbvre, with Stéphane Silvente serving as CEO since 2018. | Pharmaceuticals: Major | Director/Board Member | |
AstriVax NV
AstriVax NV BiotechnologyHealth Technology AstriVax NV, founded in 2022 by Hanne Callewaert, is a privately held Belgian company based in Leuven. AstriVax NV is located in the Biohub in Leuven and has secured a seed round of €30 million to continue building the vaccine technology. The Belgian company aims to address challenges in vaccinology with its innovative plug-and-play vaccine platform. AstriVax develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases. Supported by well-known investors, AstriVax is committed to addressing real-world challenges in vaccinology. The company's mission is to fast forward the clinical development of game-changing vaccines, creating thermostable and durable vaccines that provide polyfunctional protection. AstriVax's portfolio includes indications such as yellow fever and rabies. | Biotechnology | Chairman | |
Cellaïon SA
Cellaïon SA BiotechnologyHealth Technology Cellaïon SA is a biotech company located in Mont Saint Guibert, Belgium. Cellaïon aims to restore a favorable environment to reboost the regenerative process of the liver and ensure a second life to the native liver instead of losing it. The Belgian company has a strong IP base issued from their own research and academic research at UCLouvain, developed with the objective to generate new products. Cellaïon's treatment covers the wide spectrum of liver diseases, from the highly life-threatening acute-on-chronic liver-failure (ACLF) and acute alcoholic hepatitis, to intermediate severity acute decompensation of cirrhosis (AD) and progressive chronic liver diseases caused by non-alcoholic steatohepatitis (NASH). The company has built up a series of R&D and collaborative partnerships with both industrial and academic partners, allowing Cellaïon to broaden and accelerate its clinical development. The company was founded by Etienne Marc Sokal, who has been the CEO since incorporation. | Biotechnology | Director/Board Member | |
Inivata Ltd.
Inivata Ltd. Packaged SoftwareTechnology Services Inivata Ltd. develops new clinical applications for ctDNA analysis. It is a clinical cancer genomics company harnessing the potential of circulating tumour DNA (ctDNA) analysis to improve cancer testing and treatment. The firm is focused on developing clinical applications of ctDNA through collaborations with clinical oncologists at prominent academic institutions, leading community treatment centres and innovative biopharmaceutical companies. The company was founded by James Brenton, Tim Forshew, Rosenfeld Nitzan and Davina Gale on July 23, 2014 and is headquartered in Cambridge, the United Kingdom. | Packaged Software | Director/Board Member |
Statistieken
Internationaal
België | 18 |
Verenigd Koninkrijk | 11 |
Verenigde Staten | 9 |
Spanje | 6 |
Nederland | 4 |
Sectoraal
Health Technology | 29 |
Finance | 9 |
Consumer Services | 5 |
Commercial Services | 4 |
Health Services | 4 |
Operationeel
Director/Board Member | 39 |
Chairman | 7 |
Private Equity Investor | 6 |
Independent Dir/Board Member | 4 |
Chief Tech/Sci/R&D Officer | 4 |
Sterkste connecties
- Beurs
- Insiders
- Stef Heylen
- Bedrijfsconnecties